UBS O'Connor’s Halozyme HALO Stock Holding History

UBS O'Connor’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,000	Closed	-$37.5K	–	592
2023 Q2	$37.5K	Buy	+30,000	New	+$1.02M	﹤0.01%	514

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS O'Connor's HALO Position: Q4 2024 in Review

UBS O'Connor sold out of Halozyme (HALO) in Q4 2024, closing a stake of 24,683 shares — an estimated $1.41M sold.

UBS O'Connor first reported a position in HALO in Q2 2022 and held it in 9 quarters. The position peaked at $3.87M in Q2 2022. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

UBS O'Connor reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
UBS O'Connor sold 24,683 Halozyme shares in Q4 2024, an estimated $1.41M.
UBS O'Connor first reported a position in Halozyme in Q2 2022 and held it in 9 quarters.
UBS O'Connor's Halozyme position peaked at $3.87M in Q2 2022.
508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.